<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0112222955
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DIPHERELINE P.R. 11.25 mg Powder for Suspension for Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TRIPTORELIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        11.25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1204
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="IPSEN PHARMA BIOTECH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            IPSEN PHARMA BIOTECH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            IPSEN PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02AE04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient in Diphereline P.R. 11.25 mg is triptorelin. Triptorelin belongs to a group of medicines called<br />gonadotropin releasing hormone (GnRH) agonists. Triptorelin is similar to the gonadotropin releasing hormone<br />which occurs naturally in your body.<br />In men, triptorelin lowers the levels of the hormone testosterone.<br />In women, it reduces oestrogen levels.<br />Diphereline P.R. 11.25 mg has three different uses. It is used in men, women and children to treat completely<br />different conditions.<br />Diphereline P.R. is available in two other strengths: Diphereline P.R. 3 mg is used once a month and Diphereline<br />P.R. 22.5 mg is used once every 6 months. Not all dose strengths are approved for all indications. Ask your doctor if<br />you would like to discuss changing your treatment.<br />This lea et gives information for all three uses of Diphereline P.R. 11.25 mg. Please read all the sections that<br />are about you and your condition.<br />MEN<br />In men, Diphereline P.R. 11.25 mg is used to treat prostate cancer.<br />WOMEN<br />In women, Diphereline P.R. 11.25 mg is used to treat Endometriosis - a condition in which the tissue that<br />normally lines the uterus (endometrium) grows in other places.<br />CHILDREN<br />In children, Diphereline P.R. 11.25 mg is used to treat Puberty that occurs at a very young age (Precocious<br />Puberty). This is called &lsquo;early puberty&rsquo; in the rest of this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MEN<br />Do not use Diphereline P.R. 11.25 mg:<br />∙ If you are allergic to triptorelin or similar types of drugs (other GnRH agonists) or any of the other ingredients<br />of this medicine (listed in section 6).<br />Warnings and precautions:<br />∙ There have been reports of depression in patients taking Diphereline P.R. 11.25 mg which may be severe. If<br />you are taking Diphereline P.R. 11.25 mg and develop depressed mood, inform your doctor.<br />∙ If you are using medicines for delaying your normal blood clotting, you may experience bruising at the site of<br />injection.<br />∙ In adults if triptorelin or other GnRH agonists are used for a long period of time you may increase the risk<br />of developing thin or weak bones, especially if you are a heavy drinker, a smoker, have a family history of<br />osteoporosis (a condition that affects the strength of your bones), have a poor diet or take anticonvulsants<br />(medicines for epilepsy or ts) or corticosteroids (steroids). If you have anything wrong with you that affects<br />your bones, such as osteoporosis, tell your doctor. This may affect the way your doctor decides to treat you.<br />∙ When you rst start treatment with Diphereline P.R. 11.25 mg it actually increases the level of your hormones<br />for a short time. This means that you may feel worse to begin with (see section 4 &lsquo;Possible side effects&rsquo; for<br />more information). The doctor may give you some medicine (an anti-androgen) to prevent your symptoms<br />from getting worse. After a short time the amount of hormone will drop and your symptoms will get better.<br />∙ During the rst weeks of treatment, Diphereline P.R. 11.25 mg may, in isolated cases, and in common with<br />other GnRH agonists, cause the spinal cord to compress or the urethra (where you pass urine) to block. You<br />will be monitored by your doctor and given treatment for these conditions if they occur.<br />∙ Tell your doctor if you have diabetes.<br />∙ Tell your doctor if you have any heart or blood vessel conditions, including heart rhythm problems (arrhythmia),<br />or are being treated with medicines for these conditions. The risk of heart rhythm problems may be<br />increased when using Diphereline P.R. 11.25 mg.<br />∙ If you have an enlargement (benign tumour) of the pituitary gland that you were unaware of, this may be<br />discovered during treatment. Symptoms include sudden headache, problems with eyesight and paralysis of the<br />eye muscles.<br />∙ Tell your doctor if you notice blood in your urine or if you nd it dif cult or painful to urinate.<br />∙ Tell your doctor if you have back pain, weakness, numbness or tingling in your legs.<br />Your doctor may give you another drug to help you feel better during this time.<br />Other medicines and Diphereline P.R. 11.25 mg:<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Diphereline P.R. 11.25 mg might interfere with some medicines used to treat heart rhythm problems (e.g. quinidine,<br />procainamide, amiodarone and sotalol) or might increase the risk of heart rhythm problems when used with some<br />other drugs (e.g. methadone (used for pain relief and part of drug addiction detoxi cation), moxi oxacin (an<br />antibiotic), antipsychotics used for serious mental illnesses).<br />Drugs which increase the level of a hormone called prolactin may react with Diphereline P.R. 11.25 mg. Many<br />different kinds of drugs may increase prolactin levels.<br />Driving and using machines:<br />You may feel dizzy, tired or have problems with your sight such as blurred vision. These are possible side effects<br />of treatment or from the underlying disease. If you experience any of these side effects, you should not drive or use<br />machines.</p><p>WOMEN<br />Do not use Diphereline P.R. 11.25 mg:<br />∙ If you are allergic to triptorelin or similar types of drugs (other GnRH agonists) or any of the other ingredients<br />of this medicine (listed in section 6).<br />∙ If you are pregnant or breast-feeding.<br />Warnings and precautions:<br />∙ There have been reports of depression in patients taking Diphereline P.R. 11.25 mg which may be severe. If<br />you are taking Diphereline P.R. 11.25 mg and develop depressed mood, inform your doctor.<br />∙ If you are using medicines for delaying your normal blood clotting, you may experience bruising at the site of<br />injection.<br />∙ In adults if triptorelin or other GnRH agonists are used for a long period of time you may increase the risk<br />of developing thin or weak bones, especially if you are a heavy drinker, a smoker, have a family history of<br />osteoporosis (a condition that affects the strength of your bones), have a poor diet or take anticonvulsants<br />(medicines for epilepsy or ts) or corticosteroids (steroids). If you have anything wrong with you that affects<br />your bones, such as osteoporosis, tell your doctor. This may affect the way your doctor decides to treat you.<br />∙ When you rst start treatment with Diphereline P.R. 11.25 mg it actually increases the level of your hormones<br />for a short time. This means that you may feel worse to begin with (see section 4 &lsquo;Possible side effects&rsquo; for<br />more information). After a short time the amount of hormone will drop and your symptoms will get better.<br />∙ Tell your doctor if you have diabetes.<br />∙ Tell your doctor if you have any heart conditions.<br />∙ If you have an enlargement (benign tumour) of the pituitary gland that you were unaware of, this may be<br />discovered during treatment. Symptoms include sudden headache, problems with eyesight and paralysis of the<br />eye muscles.<br />∙ You may have some vaginal bleeding in the rst month of treatment. After that your periods normally stop.<br />∙ Tell your doctor if you have bleeding after the rst month of treatment.<br />∙ Your periods should start about 5 months after the last injection.<br />You must use some form of contraception other than the &lsquo;pill&rsquo; while you are having treatment and until you<br />start your next period. Your doctor may suggest using a barrier method of contraception such as a condom or<br />diaphragm (cap).<br />Other medicines and Diphereline P.R. 11.25 mg:<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Drugs which increase the level of a hormone called prolactin may react with Diphereline P.R. 11.25 mg. Many<br />different kinds of drugs may increase prolactin levels.<br />Pregnancy and breast-feeding:<br />Do not take Diphereline P.R. 11.25 mg if you are pregnant or breast-feeding.<br />Driving and using machines:<br />You may feel dizzy, tired or have problems with your sight such as blurred vision. These are possible side effects<br />of treatment or from the underlying disease. If you experience any of these side effects, you should not drive or use<br />machines.<br />CHILDREN<br />Do not use Diphereline P.R. 11.25 mg:<br />∙ If you are allergic to triptorelin or similar types of drugs (other GnRH agonists) or any of the other ingredients<br />of this medicine (listed in section 6).<br />Warnings and precautions:<br />∙ There have been reports of depression in patients taking Diphereline P.R. 11.25 mg which may be severe. If<br />you are taking Diphereline P.R. 11.25 mg and develop depressed mood, inform your doctor.<br />∙ If you are using medicines for delaying your normal blood clotting, you may experience bruising at the site of<br />injection.<br />∙ If you have a progressive brain tumour, tell your doctor. This may affect the way your doctor decides to treat<br />you.<br />∙ Girls who have an early puberty may have some vaginal bleeding in the rst month of treatment.<br />∙ Tell your doctor if you have diabetes.<br />∙ Tell your doctor if you have any heart conditions.<br />∙ If you have an enlargement (benign tumour) of the pituitary gland that you were unaware of, this may be<br />discovered during treatment. Symptoms include sudden headache, problems with eyesight and paralysis of the<br />eye muscles.<br />Other medicines and Diphereline P.R. 11.25 mg:<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Drugs which increase the level of a hormone called prolactin may react with Diphereline P.R. 11.25 mg. Many<br />different kinds of drugs may increase prolactin levels.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MEN</p><p>Diphereline P.R. 11.25 mg will be injected into a muscle, usually your bottom, by a doctor or nurse. On this leaflet<br />there are instructions for them that explain how to prepare the injection.<br />You will normally receive an injection once every 3 months.<br />Also read &lsquo;Other medicines and Diphereline P.R. 11.25 mg&rsquo; in section 2.<br />If you are given more Diphereline P.R. 11.25 mg than you should:<br />If you are given too much Diphereline P.R. 11.25 mg you may experience additional or more severe side effects<br />(see section 4 &lsquo;Possible side effects&rsquo;).<br />If you forget to take a dose of Diphereline P.R. 11.25 mg:<br />As soon as you realise that you have missed an injection you should tell your doctor. You will then be given your<br />next injection.<br />If you stop receiving Diphereline P.R. 11.25 mg:<br />If you stop receiving your Diphereline P.R. 11.25 mg injection before your doctor tells you to then your symptoms<br />are likely to return.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.<br />WOMEN</p><p>Diphereline P.R. 11.25 mg will be injected into a muscle, usually your bottom, by a doctor or nurse. On this leaflet<br />there are instructions for them that explain how to prepare the injection.<br />You will normally receive two injections, the second one three months after the first. Each injection will be given in<br />the first five days of your period.<br />Also read &lsquo;Other medicines and Diphereline P.R. 11.25 mg&rsquo; in section 2.<br />If you are given more Diphereline P.R. 11.25 mg than you should:<br />If you are given too much Diphereline P.R. 11.25 mg you may experience additional or more severe side effects<br />(see section 4 &lsquo;Possible side effects&rsquo;).<br />If you forget to take a dose of Diphereline P.R. 11.25 mg:<br />As soon as you realise that you have missed an injection you should tell your doctor. You will then be given your<br />next injection.<br />If you stop receiving Diphereline P.R. 11.25 mg:<br />If you stop receiving your Diphereline P.R. 11.25 mg injection before your doctor tells you to then your symptoms<br />are likely to return.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.<br />CHILDREN</p><p style="text-indent:50px">Diphereline P.R. 11.25 mg will be injected into a muscle, usually your bottom, by a doctor or nurse. On this leaflet<br />there are instructions for them that explain how to prepare the injection.<br />You will normally receive an injection once every 3 months.<br />Your doctor will decide when treatment should be stopped (normally when you are about 12 if you are a girl and<br />about 13-14 if you are a boy).<br />Also read &lsquo;Other medicines and Diphereline P.R. 11.25 mg&rsquo; in section 2.<br />If you are given more Diphereline P.R. 11.25 mg than you should:<br />If you are given too much Diphereline P.R. 11.25 mg you may experience additional or more severe side effects<br />(see section 4 &lsquo;Possible side effects&rsquo;).<br />If you forget to take a dose of Diphereline P.R. 11.25 mg:<br />As soon as you realise that you have missed an injection you should tell your doctor. You will then be given your<br />next injection.<br />If you stop receiving Diphereline P.R. 11.25 mg:<br />If you stop receiving your Diphereline P.R. 11.25 mg injection before your doctor tells you to then your symptoms<br />are likely to return.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Diphereline P.R. 11.25 mg can have side effects although not everybody gets them.<br />In rare cases you may experience a severe allergic reaction. Tell your doctor immediately if you develop<br />symptoms such as swallowing or breathing problems, a rash, swelling of your lips, face, throat or tongue.<br />MEN<br />Many of the side effects are expected, due to the change in the level of testosterone in your body. These effects<br />include hot flushes, impotence and decreased libido.<br />Side effects which are very common (may affect more than 1 in 10 people) are hot flushes, weakness, excessive<br />sweating, back pain, pins and needles sensation in the legs, reduced libido and impotence.<br />Side effects which are common (may affect up to 1 in 10 people) are nausea, dry mouth, pain, bruising, redness and<br />swelling at injection site, muscle and bone pain, pain in the arms and legs, oedema (build-up of fluid in the body<br />tissues), lower abdominal pain, high blood pressure, allergic reaction, increase in weight, dizziness, headache, loss<br />of libido, depression and mood changes.<br />Side effects which are uncommon (may affect up to 1 in 100 people) are increase of blood platelets, feeling<br />your heartbeat, ringing in the ears, vertigo, blurred vision, pain in abdomen, constipation, diarrhoea, vomiting,<br />drowsiness, severe shivering associated with sweating and a fever, sleepiness, pain, some blood tests affected<br />(including raised liver function tests), blood pressure increased, weight loss, loss of appetite, increase of appetite,<br />gout (severe pain and swelling in the joints usually in the big toe), diabetes, excessive lipids in the blood, joint pain,<br />muscle cramp, muscle weakness, muscle pain, swelling and tenderness, bone pain, tingling or numbness, inability<br />to sleep, feeling of irritability, development of enlarged breasts in men, breast pain, reduction in testicular size,<br />pain in testicles, difficulty in breathing, acne, hair loss, itching, rash, redness of skin, hives waking up to pass urine,<br />problems passing urine and nosebleeds.<br />Side effects which are rare (may affect up to 1 in 1,000 people) are red or purple discolorations on the skin, abnormal<br />sensation in the eye, blurring or disturbance in vision, sensation of fullness in the abdomen, flatulence, abnormal<br />sense of taste, chest pain, difficulty in standing, flu-like symptoms, fever, anaphylactic reaction (serious allergic<br />reaction which can cause dizziness or difficulty in breathing), inflammation of the nose/throat, increased body<br />temperature, stiff joints, joint swelling, musculoskeletal stiffness, osteoarthritis, memory loss, feeling confused,<br />decreased activity, having a feeling of elation, shortness of breath when lying flat, blisters and low blood pressure.<br />During post-marketing surveillance the following side effects have also been reported: changes in ECG (QT prolongation),<br />anaphylactic reaction (serious allergic reaction which causes difficulty in breathing or dizziness), general<br />discomfort, anxiety, rapid formation of wheals due to swelling of the skin or mucous membranes and urinary<br />incontinence.<br />As with other GnRH agonists, an increase in white blood cell count may be found in patients being treated with<br />Diphereline P.R. 11.25 mg.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet<br />By reporting side effects, you can help provide more information on the safety of this medicine.<br />WOMEN<br />Many of the side effects are expected due to the change in the level of oestrogens in your body.</p><p>These very common side effects (may affect more than 1 in 10 people) include headache, decreased libido, mood<br />swings, difficulty in sleeping, breast disorder, ovarian hyperstimulation syndrome, pain during or after sexual<br />intercourse, painful periods, genital bleeding, pelvic pain, dryness of the vagina, excessive sweating, acne, oily skin<br />and hot flushes.<br />Side effects which are common (may affect up to 1 in 10 people) are breast pain, muscle cramps, painful joints,<br />weight gain, feeling sick, depression, nervousness, abdominal pain or discomfort, pain, bruising, redness and swelling<br />at injection site, swelling and tenderness, allergic reaction, pain in the arms and legs, dizziness.<br />Side effects which are uncommon (may affect up to 1 in 100 people) are feeling your hearbeat, vertigo, dry<br />eye, blurred vision, bloating, vomiting, diarrhoea, dry mouth, flatulence, mouth ulcer, weight decrease, decrease<br />in appetite, water retention, back pain, muscle pain, abnormal taste, loss of sensations, temporary loss of<br />consciousness, memory loss, lack of concentration, tingling or numbness, involuntary muscle movement, mood<br />change, anxiety, disorientation, bleeding after sex, prolapse, irregular period, painful period and heavy period, small<br />cysts (swelling) on the ovaries which can cause pain, discharge from the vagina, difficulty breathing, nosebleed,<br />hair loss, dry skin, excessive bodily hair, brittle nails, itching, hives and skin rash.<br />During post-marketing surveillance the following side effects have also been reported: general discomfort,<br />increased blood pressure, increased body temperature, anaphylactic reaction (serious allergic reaction which<br />causes difficulty in breathing or dizziness), some blood tests affected (including raised liver function tests) muscle<br />weakness, confusion, absence of menstrual periods, rapid formation of wheals due to swelling of the skin or<br />mucous membranes, abnormal sensations in the eyes and/or changes in sight.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet&nbsp;By reporting side effects, you can help provide more information on the safety of this medicine.<br />CHILDREN<br />Side effects which are very common (may affect more than 1 in 10 people) include vaginal bleeding which may<br />occur in girls in the first month of treatment.<br />Side effects which are common (may affect up to 1 in 10 people) include pain in abdomen, pain bruising, redness<br />and swelling at injection site, headache, hot flushes, weight gain, acne, hypersensitivity reactions.<br />Side effects which are uncommon (may affect up to 1 in 100 people) are blurred vision, vomiting, constipation,<br />nausea, general discomfort, overweight, neck pain, changes in mood, pain in breast, nosebleeds, itching, rash or<br />hives in the skin.<br />During post-marketing surveillance the following side effects have also been reported: high blood pressure, abnormal<br />vision, anaphylactic reaction (serious allergic reaction which causes difficulty of breathing or dizziness) seen in<br />adult men and women, some blood tests affected include hormone levels, rapid formation of wheals due to swelling<br />of the skin or mucous membranes, muscle pain, mood disorders, depression, nervousness.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet<br />By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use the vial or ampoule after the expiry date printed on the box.<br />This medicine should not be stored above 25&deg;C. The vial and ampoule should be kept in the outer box.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away<br />medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance of Diphereline P.R. 11.25 mg is triptorelin. Each vial contains sufficient quantity of triptorelin<br />(as triptorelin pamoate) to ensure that the minimum triptorelin quantity injected is 11.25 mg.<br />The other ingredients are D,L lactide-glycolide copolymer, mannitol, carmellose sodium, polysorbate 80.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Each pack contains:
1 clear glass vial with a rubber stopper and an aluminium cap containing the powder
1 glass ampoule containing the suspension vehicle
1 syringe
2 needles.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-indent:50px">Marketing Authorisation Holder&nbsp;<br />IPSEN PHARMA&nbsp;<br />65 QUAI GEORGES GORSE&nbsp;<br />92100 BOULOGNE-BILLANCOURT, France&nbsp;</p><p style="text-indent:50px">&nbsp;Manufacturer<br />&nbsp;Ipsen Pharma Biotech,<br />&nbsp;Parc d&rsquo;Activite du plateau de signes<br />&nbsp;83870 SIGNES , France<br />To reports any side effect(s):<br />∙ Saudi Arabia: ∙ Oman:<br />The National Pharmacovigilance Centre (NPC): Department of Pharmacovigilance &amp; Drug Information<br />Fax: +966-11-205-7662 Phone No.: +968 22357686, 7687<br />Call NPC at +966-11-2038222, Ext 2317-2356-2340 Fax: +968 22358489<br />SFDA Call Center: 19999 Website: www.moh.gov.om</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in July 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المادة الفعالة في ديفيريلين بي آر ۱۱٫۲٥ مجم هي تريبتوريلين. وينتمي تريبتوريلين إلى مجموعة من الأدوية تُسمى ناهضات هرمون<br />ويشبه تريبتوريلين هرمون إفراز الغدد التناسلية الذي يحدث بشكل طبيعي في جسمك. .(GnRH) الغونادوتروبين<br />لدى الرجال، يخفّض تريبتوريلين مستويات هرمون التستوستيرون.<br />لدى النساء، يقلل مستويات هرمون الإستروجين.<br />يسُتخدم ديفيريلين بي آر ۱۱٫۲٥ مجم في ثلاثة استخدامات مختلفة. ويتم استخدامه للرجال والنساء والأطفال لعلاج أمراض مختلفة تمامًا.<br />يتوفر ديفيريلين بي آر بتركيزين آخرين: ديفيريلين بي آر ۳ مجم يسُتخدم مرة واحدة شهرياًّ، وديفيريلين بي آر ۲۲،٥ مجم يسُتخدم مرة واحدة<br />كل ٦ أشهر. ولم تتم الموافقة على جميع تركيزات الجرعات لجميع دواعي الاستعمال. اسأل طبيبك إذا كنت ترغب في مناقشة تغيير العلاج.<br />تعطي هذه النشرة معلومات عن جميع الاستخدامات الثلاثة لدواء ديفيريلين بي آر ۱۱٫۲٥ مجم. يرجى قراءة جميع الأقسام التي تخصك أنت<br />وتتناسب مع حالتك.<br />الرجال<br />عند الرجال، يسُتخدم ديفيريلين بي آر ۱۱٫۲٥ مجم لعلاج سرطان البروستات.<br />النساء<br />عند النساء، يسُتخدم ديفيريلين بي آر ۱۱٫۲٥ مجم لعلاج الانْتبِاذ البطِاَنيِّ الرَحِمِيّ - حالة مرضية ينتج عنها نمو الأنسجة التي تشكل الرحم عادة<br />(بطانة الرحم) في أماكن أخرى.<br />الأطفال<br />بالنسبة للأطفال، يُستخدم ديفيريلين بي آر ۱۱٫۲٥ مجم لعلاج مرحلة البلوغ التي تحدث في سن مبكرة جدًّا (بلوغ مبكّر). سوف يسمى هذا<br />في بقية هذه النشرة. &laquo; لبلوغ المبكّر &raquo;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>الرجال<br />لا تستخدم ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />&bull; إذا كان لديك حساسية من دواء تريبتوريلين أو أي أدوية أخرى مشابهة (المنشطات الأخرى للهرمون المُوَجِّه للغدد التناسلية) أو أي من<br />.( المكوّنات الأخرى لهذا الدواء (المدرجة في القسم ٦<br />التحذيرات والاحتياطات:<br />&bull; تم الإبلاغ عن إصابة المرضى الذين يتناولون ديفيريلين بي آر ۱۱٫۲٥ مجم بالاكتئاب وقد يكون شديدًا. وإذا كنت تتناول ديفيريلين بي آر<br />۱۱٫۲٥ مجموتسبب لك في حالة مزاجية مكتئبة، فأخبر طبيبك.<br />&bull; إذا كنت تستخدم أدوية لتأخير تخثر الدم الطبيعي، فقد تُصاب بكدمات في موقع الحقن.<br />&bull; عند البالغين، إذا تم استخدام تريبتوريلين أو المنشطات الأخرى للهرمون المُوَجِّه للغدد التناسلية لفترة طويلة، قد تسبب هذه الأدوية بزيادة<br />خطر الإصابة بهشاشة أو ضعف العظام، خاصة إذا كنت مدمن كحول أو مدخنا شرها ولديك تاريخ عائلي من مرض هشاشة العظام<br />(حالة مرضية تؤثر في قوة عظامك)، أو كنت تتبع نظامًا غذائيا سيئا،ً أو تتناول مضادات الاختلاج (أدوية لعلاج الصرع أو النوبات)، أو<br />الكورتيكوستيرويدات (الستيرويدات). وإذا لديك أي أعراض أخرى في عظامك، مثل هشاشة العظام، فأخبر طبيبك؛ فقد يؤثر ذلك على<br />الطريقة التي يقرر طبيبك معالجتك بها.<br />&bull; عندما تبدأ العلاج بديفيريلين بي آر ۱۱٫۲٥ مجم لأول مرة، فإنه يزيد بالفعل من مستوى الهرمونات لديك لفترة قصيرة. وهذا يعني أنك قد<br />تشعر بأن الحالة أصبحت أسوأ عند بداية العلاج باستخدام الدواء(ارجع إلى القسم ٤&quot; الآثار الجانبية المحتملة&quot; للحصول على المزيد من<br />المعلومات). وقد يعطيك الطبيب بعض الأدوية (مضادات الأندروجين) لمنع الأعراض من التفاقم. وبعد وقت قصير، سوف تنخفض كمية<br />الهرمون وستتحسن أعراضك.<br />&bull; خلال الأسابيع الأولى من العلاج، قد يؤدي ديفيريلين بي آر ۱۱٫۲٥ مجم في الحالات المنفردة، وفي حالة تناوله مع المنشطات الأخرى<br />للهرمون المُوَجِّه للغدد التناسلية، إلى ضغط الحبل الشوكي أو انسداد مجرى البول(حيث يمر البول). وسيقوم طبيبك بمراقبتك وستتلقى<br />العلاج لهذه الحالات إذا حدثت.<br />&bull; أخبر طبيبك إذا كان لديك مرض السكري.<br />&bull; أخبر طبيبك اذا كنت تعاني من أي من أمراض القلب أو الأوعية الدموية، بما في ذلك مشكلات ضربات القلب (عدم انتظام ضربات القلب)،<br />أو في حالة تناول الأدوية لعلاج هذه الحالات المرضية؛ إذ يمكن زيادة خطر التعرض لمشكلات في ضربات القلب عند استخدام ديفيريلين<br />بي آر ۱۱٫۲٥ مجم.<br />&bull; إذا كان لديك توَرُّم (ورم حميد) غير مدرك له في الغدة النخامية، فقد يتم اكتشاف ذلك في أثناء العلاج. وتشمل الأعراض صداعًا مفاجئا،ً<br />ومشكلات في البصر، وشللاً في عضلات العين.<br />&bull; أخبر طبيبك إذا لاحظت وجود دم في البول، أو إذا كنت تجد صعوبة أو تشعر بألم عند التبول.<br />&bull; أخبر طبيبك إذا كنت تعاني من آلام الظهر، وضعف أو خدر أو وخز في ساقيك. قد يعطيك طبيبك دواء آخر لمساعدتك على الشعور بتحسن<br />خلال هذا الوقت.<br />استخدام الأدوية الأخرى مع ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول حالياًّ، أو تناولت مؤخرًا أو قد تتناول في المستقبل، أي أدوية أخرى.<br />قد يتداخل ديفيريلين بي آر مع بعض الأدوية المستخدمة لعلاج مشاكل ضربات القلب (مثل: الكينيدين والبروكيناميد والأميودارون والسوتالول)،<br />أو قد يزيد من خطر حدوث مشكلات في ضربات القلب عند استخدامه مع بعض الأدوية الأخرى (مثل: الميثادون (يسُتخدم لتخفيف الآلام وإزالة<br />السموم الناتجة من إدمان المخدرات)، وموكسيفلوكساسين (مضاد حيوي)، ومضادات الذهان المستخدمة في الأمراض العقلية الخطيرة).<br />الأدوية التي تزيد مستوى هرمون يسمى البرولاكتين قد تتفاعل مع ديفيريلين بي آر ۱۱٫۲٥ مج موقد تزيد أنواع مختلفة من الأدوية من مستويات<br />البرولاكتين.<br />القيادة واستخدام الآلات:<br />قد تشعر بالدوار أو التعب أو الإصابة بمشكلات في الإبصار مثل عدم وضوح الرؤية. وهذه هي الآثار الجانبية المحتملة للعلاج أو المرض<br />الأساسي. فإذا كنت تواجه أياًّ من هذه الآثار الجانبية، يجب ألا تقود أو تستخدم الآليات.<br />النساء<br />لا تستخدمي ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />&bull; إذا كان لديكِ حساسية من دواء تريبتوريلين أو أي أدوية أخرى مشابهة (المنشطات الأخرى للهرمون المُوَجِّه للغدد التناسلية) أو أي من<br />.( المكوّنات الأخرى لهذا الدواء (المدرجة في القسم ٦<br />&bull; إذا كنتِ حاملاً أو تمارسين الرضاعة الطبيعية.</p><p>التحذيرات والاحتياطات:<br />&bull; تم الإبلاغ عن إصابة المرضى الذين يتناولون ديفيريلين بي آر ۱۱٫۲٥ مجم بالاكتئاب وقد يكون شديدًا. فإذا<br />كنتِ تتناولين ديفيريلين بي آر ۱۱٫۲٥ مجم وقد تسبب هذا في حالة مزاجية مكتئبة، فأخبري طبيبك.<br />&bull; إذا كنتِ تستخدمين أدوية لتأخير تخثر الدم الطبيعي، فقد تُصابين بكدمات في موقع الحقن.<br />&bull; عند البالغين، إذا تم استخدام تريبتوريلين أو المنشطات الأخرى للهرمون المُوَجِّه للغدد التناسلية لفترة طويلة، قد<br />تسبب هذه الأدوية بزيادة خطر الإصابة بهشاشة أو ضعف العظام، خاصة إذا كنتِ مدمنة للكحول أو مدخنة شرهة،<br />ولديكِ تاريخ عائلي من مرض هشاشة العظام (حالة مرضية تؤثر على قوة عظامك)، أو كنتِ تتبعين نظامًا غذائيًا<br />سيئاً، أو تتناولين مضادات الاختلاج (أدوية لعلاج الصرع أو النوبات)، أو الكورتيكوستيرويدات (الستيرويدات).<br />وإذا لديك أي أعراض أخرى في عظامك، مثل هشاشة العظام، فأخبري طبيبك؛ فقد يؤثر ذلك في الطريقة التي يقرر<br />طبيبك معالجتك بها.</p><p>عندما تبدأين العلاج باستخدام ديفيريلين بي آر ۱۱٫۲٥ مجم لأول مرة، فإنه يزيد بالفعل من مستوى الهرمونات لديك لفترة قصيرة. وهذا<br />يعني أنك قد تشعرين بأن الحالة أصبحت أسوأ عند بداية العلاج باستخدام الدواء (ارجعي إلى القسم ٤) &quot;الآثار الجانبية المحتملة&quot; للحصول<br />على مزيد من المعلومات). وبعد وقت قصير، سوف تنخفض كمية الهرمون وستتحسن أعراضك.<br />&bull; أخبري طبيبك إذا كنتِ مصابة بالسكري.<br />&bull; أخبري طبيبك إذا كانت لديك أي مشاكل في القلب.<br />&bull; إذا كان لديكِ توَرُّم (ورم حميد) غير مدركة له في الغدة النخامية، فقد يتم اكتشاف ذلك في أثناء العلاج. وتشمل الأعراض صداعًا مفاجئاً،<br />ومشكلات في البصر، وشللاً في عضلات العين.<br />&bull; قد تصابين بنزيف مهبلي في الشهر الأول من العلاج. وتتوقف الدورة الشهرية بعد ذلك طبيعيًّا.<br />&bull; أخبري طبيبك إذا أصبتِ بنزيف بعد الشهر الأول من العلاج.<br />&bull; ينبغي أن تبدأ دورتك الشهرية بعد مرور ٥ أشهر تقريبًا من آخر حقنة.<br />يجب عليك استخدام وسيلة من وسائل منع الحمل غير &quot;حبوب منع الحمل&quot; في أثناء العلاج، وحتى تعود دورتك الشهرية مرة أخرى. وقد يقترح<br />طبيبك استخدام وسيلة لمنع الحمل، مثل الواقي الذكري أو العَازِل الأنُثوَيّ.<br />استخدام ديفيريلين بي آر مع الأدوية الأخرى ۱۱٫۲٥ مجم:<br />أخبري طبيبك أو الصيدلي إذا كنت تتناولين حالياًّ، أو تناولتِ مؤخرًا أو قد تتناولين في المستقبل، أي أدوية أخرى.<br />الأدوية التي تزيد مستوى هرمون يسمى البرولاكتين قد تتفاعل مع ديفيريلين بي آر ۱۱٫۲٥ مجم، وقد تزيد أنواع مختلفة من الأدوية من مستويات<br />البرولاكتين.<br />الحمل والرضاعة الطبيعية:<br />لا تستخدمي ديفيريلين بي آر ۱۱٫۲٥ مجم إذا كنتِ حاملاً أو تمارسين الرضاعة الطبيعية.<br />القيادة واستخدام الآلات:<br />قد تشعرين بالدوار أو التعب أو الإصابة بمشكلات في البصر، مثل عدم وضوح الرؤية. وهذه هي الآثار الجانبية المحتملة للعلاج أو المرض<br />الأساسي. فإذا كنتِ تواجهين أياًّ من هذه الآثار الجانبية، يجب ألا تقودي أو تستخدمي الآليات.<br />الأطفال<br />لا تستخدم ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />&bull; إذا كان لديك حساسية من دواء تريبتوريلين أو أي أدوية أخرى مشابهة (المنشطات الأخرى للهرمون المُوَجِّه للغدد التناسلية) أو أي من<br />.( المكوّنات الأخرى لهذا الدواء (المدرجة في القسم ٦<br />التحذيرات والاحتياطات:<br />&bull; تم الإبلاغ عن إصابة المرضى الذين يتناولون ديفيريلين بي آر ۱۱٫۲٥ مجم بالاكتئاب وقد يكون شديدًا. وإذا كنت تتناول ديفيريلين بي<br />آر ۱۱٫۲٥ مجم وتسبب في حالة مزاجية مكتئبة، فأخبر طبيبك.<br />&bull; إذا كنت تستخدم أدوية لتأخير تخثر الدم الطبيعي، فقد تُصاب بكدمات في موقع الحقن.<br />&bull; إذا كان لديك ورم دماغي في حالة متقدمة، فأخبر طبيبك؛ فقد يؤثر ذلك على الطريقة التي يقرر طبيبك معالجتك بها.<br />&bull; الفتيات اللواتي يكون لديهن بلوغًا مُبكرًا، قد يُصبن بنزيف مهبلي في الشهر الأول من العلاج.<br />&bull; أخبر طبيبك إذا كنت مُصاباً بمرض السكري.<br />&bull; أخبر طبيبك إذا كان لديك أي مشاكل بالقلب.<br />&bull; إذا كان لديك توَرُّم (ورم حميد) غير مدرك له في الغدة النخامية، فقد يتم اكتشاف ذلك في أثناء العلاج. وتشمل الأعراض صداعًا مفاجئا،ً<br />ومشكلات في البصر، وشللاً في عضلات العين.<br />استخدام ديفيريلين بي آر مع الأدوية الأخرى ۱۱٫۲٥ مجم:<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول حالياًّ، أو تناولت مؤخرًا أو قد تتناول في المستقبل، أي أدوية أخرى.<br />الأدوية التي تزيد مستوى هرمون يسمى البرولاكتين قد تتفاعل مع ديفيريلين بي آر ۱۱٫۲٥ مجم ، وقد تزيد أنواع مختلفة من الأدوية من مستويات<br />البرولاكتين</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>الرجال<br />سوف يتم حقن ديفيريلين بي آر ۱۱٫۲٥ مجم في العضل، عادة في عضلة المقعدة، من جانب طبيب أو ممرضة. وتتضمن هذه النشرة إرشادات<br />خاصة بهم تشرح كيفية تحضير الحقن.<br />عادة، سوف تؤخذ حقنة مرة واحدة كل ۳ أشهر.<br />. اقرأ أيضًا &quot;ديفيريلين بي آر ۱۱٫۲٥ مجم مع الأدوية الأخرى&quot; في القسم ۲<br />إذا تم إعطاؤك جرعة زائدة عن المطلوب من ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />إذا تم إعطاؤك جرعة زئداة عن المطلوب من ديفيريلين بي آر ۱۱٫۲٥ مجم، فقد تواجه آثارًا جانبية إضافية أو أكثر شدة (انظر القسم ٤ &quot; الآثار<br />الجانبية المحتملة&quot;).<br />إذا نسيت جرعة من ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />بمجرد أن تدرك أنك قد فوَّتَّ حقنة، يجب أن تخبر طبيبك. وعندئذٍ سوف يتم إعطاؤك الحقنة التالية.<br />إذا توقفت عن حقن ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />إذا توقفت عن حقن ديفيريلين بي آر ۱۱٫۲٥ مجم قبل أن يخبرك طبيبك بالتوقف، فعندئذٍ من المرجح أن تعود لك الأعراض.<br />إذا كانت لديك أي أسئلة أخرى عن كيفية استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.<br />النساء<br />سوف يتم حقن ديفيريلين بي آر ۱۱٫۲٥ مجم في العضل، عادة في عضلة المقعد، من جانب طبيب أو ممرضة. وتتضمن هذه النشرة إرشادات<br />خاصة بهم تشرح كيفية تحضير الحقن.<br />وسوف يتم إعطاؤكِ حقنتين؛ الثانية بعد ثلاثة أشهر من الحقنة الأولى. وسيتم إعطاء كل حقنة في الأيام الخمسة الأولى من الدورة الشهرية.<br />. اقرأي أيضًا &quot;ديفيريلين بي آر ۱۱٫۲٥ مجم مع الأدوية الأخرى&quot; في القسم ۲<br />إذا تم إعطاؤك جرعة زئداة عن المطلوب من ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />إذا تم إعطاؤك جرعة زئداة عن المطلوب من ديفيريلين بي آر ۱۱٫۲٥ مجم، فقد تواجهين آثارًا جانبية إضافية أو أكثر شدة (انظري القسم ٤<br />&quot;الآثار الجانبية المحتملة&quot;).<br />إذا نسيتِ جرعة من ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />بمجرد أن تدركي أنك قد فوَّتِّي حقنة، يجب أن تخبري طبيبك. وعندئذٍ سوف يتم إعطاؤك الحقنة التالية.<br />إذا توقفتِ عن حقن ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />إذا توقفتِ عن حقن ديفيريلين بي آر ۱۱٫۲٥ مجم قبل أن يخبرك طبيبك بالتوقف، فعندئذٍ من المرجح أن تعود لك الأعراض.<br />إذا كانت لديكِ أي أسئلة أخرى عن كيفية استخدام هذا الدواء، فاسألي طبيبك أو الصيدلي.<br />الأطفال<br />سوف يتم حقن ديفيريلين بي آر ۱۱٫۲٥ مجم في العضل، عادة في عضلة المقعد، من جانب طبيب أو ممرضة. وتتضمن هذه النشرة إرشادات<br />خاصة بهم تشرح كيفية تحضير الحقن.<br />عادة، سوف تؤخذ حقنة مرة واحدة كل ۳ أشهر.<br />۱٤ تقريباً إذا كنت فتى). &ndash; سوف يقرر طبيبك متى يجب أن يتوقف العلاج (عادة عندما يبلغ عمرك ۱۲ تقريباً إذا كنتِ فتاة، أو ۱۳<br />. اقرأ أيضًا &quot;ديفيريلين بي آر ۱۱٫۲٥ مجم مع الأدوية الأخرى&quot; في القسم ۲<br />إذا تم إعطاؤك جرعة زائدة عن المطلوب من ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />إذا تم إعطاؤك جرعة زئداة عن المطلوب من ديفيريلين بي آر ۱۱٫۲٥ مجم، فقد تواجه آثارًا جانبية إضافية أو أكثر شدة (انظر القسم ٤ &quot;الآثار<br />الجانبية المحتملة&quot;).<br />إذا نسيت جرعة من ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />بمجرد أن تدرك أنك قد فوَّتَّ حقنة، يجب أن تخبر طبيبك. وعندئذٍ سوف يتم إعطاؤك الحقنة التالية.<br />إذا توقفت عن حقن ديفيريلين بي آر ۱۱٫۲٥ مجم:<br />إذا توقفت عن حقن ديفيريلين بي آر ۱۱٫۲٥ مجم قبل أن يخبرك طبيبك بالتوقف، فعندئذٍ من المرجح أن تعود لك الأعراض.<br />إذا كانت لديك أي أسئلة أخرى عن كيفية استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="text-indent:50px">مثل كل الأدوية، يمكن أن يسبب ديفيريلين بي آر ۱۱٫۲٥ مجم آثارًا جانبية، على الرغم من عدم حدوثها لكل الأشخاص.<br />في بعض الحالات النادرة، قد تتعرض لرد فعل تحسسي حاد. أبلغ طبيبك على الفور إذا شعرت بأي أعراض، مثل ظهور مشكلات في التنفس أو<br />البلع، أو طفح جلدي، أو تورم في الشفتين أو الوجه أو الحلق أو اللسان.<br />الرجال<br />من المتوقع حدوث العديد من الآثار الجانبية، بسبب التغيرُّ في مستوى هرمون التستوستيرون في جسمك. وتشمل تلك الآثار هبات الحرارة، والعجز<br />الجنسي، وانخفاض الرغبة الجنسية.<br />تتضمن الآثار الجانبية الشائعة جدًّا (قد تصيب أكثر من شخص واحد إلى ۱۰ أشخاص) هبات الحرارة والضعف والتعرق المفرط، وآلام الظهر<br />والإحساس بوخز في الساقين، وانخفاض الرغبة الجنسية والعجز الجنسي.<br />تتضمن الآثار الجانبية الشائعة (قد تصيب ما يصل إلى ۱ من كل ۱۰ مستخدمين) الغثيان وجفاف الفم والألم والكدمات والاحمرار والتورم في&nbsp;موضع الحقن، وآلامًا في العضلات والعظام، وآلامًا في الذراعين والساقين، والوذمة )تراكم السوائل في أنسجة الجسم(، وآلامًا أسفل البطن،<br />وارتفاع ضغط الدم، وردود الفعل التحسسية، وزيادة في الوزن، والدوخة، والصداع، وفقدان الرغبة الجنسية، والاكتئاب وتغيرات في الحالة<br />المزاجية.<br />تتضمن الآثار الجانبية غير الشائعة (قد تؤثر على ما يصل إلى ۱ من كل ۱۰۰ مستخدم) زيادة الصفائح الدموية، والشعور بنبض القلب، ورنين<br />في الأذنين، والدوار، وعدم وضوح الرؤية، وآلامًا في البطن، والإمساك، والإسهال، والتقيؤ، والنعاس، ورعشة شديد مصحوبة بتعرق وحمى،<br />والنعاس، والألم، وتأثر بعض اختبارات الدم (بما في ذلك ارتفاع في اختبارات وظائف الكبد)، وزيادة ضغط الدم، وفقدان الوزن، وفقدان الشهية،<br />وزيادة الشهية، والنقرس (ألم شديد وتورم في المفاصل عادة ما يكون في إصبع القدم الكبير)، والسكري، والدهون المفرطة في الدم، وآلام<br />المفاصل، وتشنج العضلات، وضعف العضلات، وآلامًا أو تورمًا أو طراوة في العضلات، وآلامًا في العظام، وخزًا أو خدرًا، وعدم القدرة على<br />النوم، والشعور بتهيج الجلد، وتزايد تضخم الثديين لدى الرجال، وآلامًا في الثدي، وتقلص حجم الخصية، وآلامًا في الخصيتين، وصعوبة في<br />التنفس، وحب الشباب، وتساقط الشعر، والحكة، والطفح الجلدي، واحمرار البشرة، وطفحًا جلدياًّ يظهر عند التبول، ومشاكل في التبول، ونزيف<br />الأنف.<br />تتضمن الآثار الجانبية النادرة (قد تؤثر على ما يصل إلى ۱ من كل ۱۰۰۰ مستخدم) ظهور بقع حمراء أو أرجوانية على الجلد، وإحساسًا غير<br />طبيعي في العين، وعدم وضوح الرؤية أو اضطرابها، والإحساس بالامتلاء في البطن، وانتفاخ البطن، وتغير في حاسة الذوق، وألمًا في الصدر،<br />وصعوبة في الوقوف، وأعراضًا تشبه الأنفلونزا، وحمى، ورد فعل تحسسي مفرط )رد فعل تحسسي خطير يمكن أن يسبب الدوار أو صعوبة في<br />التنفس)، والتهاب الأنف/الحلق، وارتفاع درجة حرارة الجسم، والمفاصل المتيبسة، وتورم المفاصل، وتصلب العضلات والعظام الهيكلية،<br />وهشاشة العظام، وفقدان الذاكرة، والشعور بالارتباك، وانخفاض النشاط، والشعور بالنشوة، وضيقاً في التنفس عند الاستلقاء، وبثورًا، وانخفاض<br />ضغط الدم. في فترة المراقبة بعد التسويق، تم الإبلاغ عن الآثار الجانبية التالية كذلك: تغيرُّات في نتائج مخطط كهربية القلب (متلازمة كيو تي<br />الطويلة)، ورد فعل تحسسي مفرط (رد فعل تحسسي خطير يسبب صعوبة في التنفس أو دوارًا)، وعدم الراحة بشكل عام، والقلق، والتشكل السريع<br />للبثور بسبب تورم الجلد أو الأغشية المخاطية، وسلس البول.<br />كما هو الحال مع منبهات الغدد التناسلية الأخرى، يمكن حدوث زيادة في عدد خلايا الدم البيضاء لدى المرضى الذين تلقوا العلاج ب ديفيريلين بي<br />آر ۱۱٫۲٥ مجم.<br />الإبلاغ عن الآثار الجانبية<br />إذا شعرت بأي آثار جانبية، فاستشر الطبيب أو الصيدلي أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة.<br />عن طريق الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.<br />النساء<br />من المتوقع حدوث العديد من الآثار الجانبية، بسبب التغير في مستوى هرمون الإستروجين في جسمكِ.<br />تتضمن الآثار الجانبية الشائعة جدًّا (قد تصيب أكثر من شخص واحد إلى ۱۰ أشخاص) الصداع وانخفاض الرغبة الجنسية وتقلب المزاج،<br />وصعوبة في النوم، واضطرابات الثدي، ومتلازمة فرط تحفيز المبيض، وألمًا في أثناء الجماع أو بعده، وآلامًا خلال فترات الدورة الشهرية،<br />ونزيفاً تناسلياًّ، وألمًا في الحوض، وجفافاً في المهبل، وفرط التعرق، حب الشباب، والبشرة الدهنية، والهبات الساخنة.<br />تتضمن الآثار الجانبية الشائعة (قد تصيب ما يصل إلى ۱ من كل ۱۰ مستخدمين) آلام الثدي، وتشنجات العضلات، وآلام المفاصل، وزيادة الوزن،<br />والشعور بالمرض، والاكتئاب، والعصبية، وآلامًا أو عدم الراحة في البطن، وآلامًا أو كدمات أو احمرارًا أو تورمًا في موقع الحقن، وتورمًا أو<br />ليونة أو رد فعل تحسسياًّ أو ألمًا في الذراعين والساقين، والدوخة.<br />تتضمن الآثار الجانبية غير الشائعة (قد تؤثر على ما يصل إلى ۱ من كل ۱۰۰ مستخدم) الشعور بنبض القلب والدوار، وجفاف العين، وعدم<br />وضوح الرؤية، والانتفاخ، والقيء، والإسهال، وجفاف الفم، وانتفاخ البطن، وقرحة الفم، وانخفاض الوزن، وانخفاض الشهية، واحتباس الماء،<br />وآلام الظهر، وآلام العضلات، وتغيرًا غير طبيعي في التذوق، وفقدان الأحاسيس، وفقدانا مؤقتا للوعي، وفقدان الذاكرة، وعدم التركيز، ووخزًا<br />أو خدرًا، وحركة لاإرادية في العضلات، والتغير في المزاج، والقلق، والارتباك، والنزيف بعد الجماع، وهبوط الرحم، وعدم انتظام في الدورة<br />الشهرية، وآلام خلال الدورة الشهرية، الدورة الشهرية الغزيرة، وخراجات صغيرة (تورم)على المبايض يمكنها أن تسبب الألم، والإفرازات<br />المهبلية، وصعوبة التنفس، ونزيف الأنف، وسقوط الشعر، وجفاف الجلد، وغزارة شعر الجسم، وهشاشة الأظافر، الحك، والشرى، والطفح الجلدي.<br />في فترة المراقبة بعد التسويق، تم الإبلاغ عن الآثار الجانبية التالية كذلك: عدم الراحة بشكل عام، وارتفاع ضغط الدم، وارتفاع درجة حرارة<br />الجسم، ورد فعل تحسسي مفرط (رد فعل تحسسي خطير يسبب صعوبة في التنفس أو دوار)، وتأثر بعض اختبارات الدم (بما في ذلك ارتفاع في<br />اختبارات وظائف الكبد)، وضعف العضلات، والارتباك، واختفاء فترات الحيض، والتشكل السريع للبثور بسبب تورم الجلد أو الأغشية المخاطية،<br />وأحاسيس غير طبيعية في العينين و/أو التغير في الإبصار.<br />الإبلاغ عن الآثار الجانبية<br />إذا شعرتِ بأي آثار جانبية، فاستشيري الطبيب أو الصيدلي أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة.<br />عن طريق الإبلاغ عن الآثار الجانبية، يمكنكِ المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.<br />الأطفال<br />تتضمن الآثار الجانبية الشائعة جدًّا (قد تصيب أكثر من شخص واحد إلى ۱۰ أشخاص) النزيف المهبلي الذي قد يحدث لدى الفتيات خلال الشهر<br />الأول من العلاج.<br />تتضمن الآثار الجانبية الشائعة (قد تصيب ما يصل إلى ۱ من كل ۱۰ مستخدمين) آلامًا في البطن، وكدمات مؤلمة، واحمرارًا وتورمًا في موضع<br />الحقن، والصداع، وهبات الحرارة، وزيادة الوزن، وحب الشباب، وردود فعل فرط الحساسية.<br />تتضمن الآثار الجانبية غير الشائعة (قد تؤثر على ما يصل إلى ۱ من كل ۱۰۰ مستخدم) عدم وضوح الرؤية، والقيء، والإمساك، والغثيان،<br />والشعور بعدم الارتياح بشكل عام، وزيادة الوزن، وآلام الرقبة، وتغيرُّات في الحالة المزاجية، وألمًا في الثدي، ونزيف الأنف، وحكة، والطفح<br />الجلدي.<br />في فترة المراقبة بعد التسويق، تم الإبلاغ عن الآثار الجانبية التالية كذلك: ضغط الدم، وعدم وضوح الرؤية، ورد فعل تحسسي مفرط (رد فعل<br />تحسسي خطير يسبب صعوبة في التنفس أو دوارًا) لدى البالغين من الرجال والنساء، وتأثر بعض اختبارات الدم، بما في ذلك مستويات الهرمون<br />التشكل السريع للبثور بسبب تورم الجلد أو الأغشية المخاطية، وآلام العضلات، واضطرابات المزاج، والاكتئاب، والعصبية.<br />الإبلاغ عن الآثار الجانبية<br />إذا شعرت بأي آثار جانبية، استشر الطبيب أو الصيدلي أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة.<br />عن طريق الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحُفظ هذا الدواء بعيدًا عن متناول الأطفال ورؤيتهم.<br />لا تستخدم القارورة أو الأمبول بعد تاريخ الانتهاء الموضح على العبوة.<br />لا يجب تخزين هذا الدواء فوق ۲٥ درجة مئوية. وتحُفظ القارورة والأمبول في العبوة الخارجية.<br />يجب عدم التخلص من الأدوية عن طريق مياه الصرف أو ضمن النفايات المنزلية. استشر الصيدلي حول كيفية التخلص من الأدوية التي لم تعد في<br />حاجة إليها. تساعد تلك الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة في ديفيريلين بي آر ۱۱٫۲٥ مجمهو التريبتوريلين. وتحتوي كل قارورة على كمية كافية من التريبتوريلين (في صورة باموات<br />التريبتوريلين) لضمان أن يكون الحد الأدنى لكمية التريبتوريلين التي يتم حقنها هي ۱۱٫۲٥ مجم.<br />. المكوّنات الأخرى هي دي إل لاكتيد - كوبولبيمير جليكوبيد والمانيتول وصوديوم الكارميلوز وبوليسوربات ۸۰</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو ديفيريلين بي آر ۱۱٫۲٥ مجم ومحتويات العبوة<br />تحتوي كل علبة على:<br />۱ قارورة زجاجية شفافة ذات سدادة مطاطية وغطاء من الألومنيوم، والتي تحتوي على المسحوق<br />۱ أمبول زجاحي يحتوي على سواغ المعلق<br />۱ محقن<br />۲ إبرة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة المالكة لحقوق التسويق والشركة المصنّعة:<br />الشركة المالكة لحقوق التسويق<br />إبسين فارما<br />65 كواي جورج غورس<br />92100 بولوني-بيلانكور<br />فرنسا<br />الشركة المصنّعة<br />إبسن فارما بيوتك<br />بارك داكتيفيتيه دو بلاتوه دو سينيه، 83870 سينيه، فرنسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في يوليو ۲۰۱۷
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DIPHERELINE P.R. 11.25 mg, powder and solvent for suspension for injection (I.M.), 3-month
prolonged release form.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Triptorelin .................................................................................................................................... 11.25 mg
as triptoréline pamoate.
For one unit dose
* Taking into account the characteristics of the pharmaceutical form, each vial contains a quantity of
triptorelin pamoate corresponding to 15 mg of triptorelin.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for suspension for injection (I.M.), prolonged release form.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prostate cancer<br />Treatment of locally advanced or metastatic prostate cancer.<br />Treatment of high-risk localised or locally advanced prostate cancer in combination with radiotherapy.<br />See section 5.1.<br />A favourable effect of the treatment is all the more pronounced and more frequent if the patient has not<br />previously received any other hormone treatment.<br /> Genital and extragenital endometriosis (stage I to IV)<br />Treatment should not be administered for more than 6 months (see section 4.8). It is not recommended<br />to undertake a second course of treatment by triptorelin or by another GnRH analogue.<br /> Central precocious puberty (before 8 years in girls and 10 years in boys).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br /> Prostate cancer :<br />One intramuscular injection of DIPHERELINE P.R. 11.25 mg repeated every 3 months.<br />Duration of the treatment:<br />In high-risk localised or &lsquo;locally advanced hormone-dependent prostate cancer as concomitant to and<br />following radiation therapy&rsquo; clinical data have shown that radiotherapy followed by long-term androgen<br />deprivation therapy is preferable to radiotherapy followed by short-term androgen deprivation therapy.<br />See section 5.1.<br />The treatment duration of androgen deprivation therapy recommended by medical guidances for<br />patients with high-risk localised or locally advanced prostate cancer receiving radiotherapy is 2-3 years.<br />For patients with metastatic prostate cancer castration-resistant, chirurgically uncastrated, treated by a<br />GnRH agonist as triptorelin, and eligible to a treatment by abiraterone acetate, an inhibitor of androgen<br />CIS : 6 000 000 0 M000/1000/003 2<br />biosynthesis or enzalutamide, an inhibitor of signalling pathway of androgen receptors, the treatment by<br />a GnRH agonist must be followed.<br /> Endometriosis :<br />One intramuscular injection of DIPHERELINE P.R. 11.25 mg repeated every 3 months.<br />The treatment must be initiated in the first five days of the menstrual cycle.<br />Treatment duration: this depends on the initial severity of the endometriosis and the changes observed<br />in the clinical features (functional and anatomical) during treatment. In principle, endometriosis should<br />be treated for at least 3 months and for at most 6 months. It is not recommended to start a second<br />treatment course with triptorelin or another GnRH analogue.<br />NB: The prolonged released form must be injected in strict compliance with the instructions given in the<br />package leaflet. Any incomplete injections resulting in the loss of suspension volumes greater than the<br />volume generally remaining in the injection syringe must be reported.<br /> Central precocious puberty :<br />The treatment of children with triptorelin should be under the overall supervision of the paediatric<br />endocrinologist or of a paediatrician or endocrinologist with expertise in the treatment of central<br />precocious puberty.<br />Children over 20 kg in body weight: one intramuscular injection of DIPHERELINE P.R. 11.25 mg<br />administered every 3 months.<br />Treatment should be stopped around the physiological age of puberty in boys and girls and it is<br />recommended that treatment is not continued in girls with bone maturation of more than 12 years. There<br />are limited data available in boys relating to the optimum time to stop treatment based on bone age,<br />however it is advised that treatment is stopped in boys with a bone maturation age of 13-14 years.<br />DIPHERELINE P.R. 11.25 mg must not be injected intravascularly.<br />For reconstitution of DIPHERELINE before use, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to GnRH, its analogues or to any of the excipients (see section
6.1).
Pregnancy and breast-feeding.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of GnRH agonists may cause reduction in bone mineral density. In men, preliminary data suggest that the use of a bisphosphonate in combination with a GnRH agonist may reduce bone mineral loss. Particular caution is necessary in patients with additional risk factors for osteoporosis (e.g. chronic alcohol abuse, smokers, long-term therapy with drugs that reduce bone mineral density, e.g. anticonvulsants or corticoids, family history of osteoporosis, malnutrition).</p><p>It should be confirmed that the patient is not pregnant before prescription of DIPHERELINE P.R. 11.25 mg.</p><p>Rarely, treatment with GnRH agonists may reveal the presence of a previously unknown gonadotroph cell pituitary adenoma. These patients may present with a pituitary apoplexy characterised by sudden headache, vomiting, visual impairment and ophthalmoplegia.</p><p>There is an increased risk of depression (which may be severe) in patients undergoing treatment with GnRH agonists, such as triptorelin. Patients should be informed accordingly and treated appropriate if symptoms occur. Patients with known depression should be monitored closely during therapy. DIPHERELINE P.R. 11.25 mg contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &ldquo;sodium-free&rdquo;.</p><p>Caution should be given to patients treated with anti-coagulants as haematoma may potentially appear at the intramuscular injection site.</p><p>Prostate cancer</p><p>Initially, triptorelin, like other GnRH agonists, causes a transient increase in serum testosterone levels. As a consequence, isolated cases of transient worsening of signs and symptoms of prostate cancer may occasionally develop during the first weeks of treatment. During the initial phase of treatment, consideration should be given to the additional administration of a suitable anti-androgen to counteract the initial rise in serum testosterone levels and the worsening of clinical symptoms.</p><p>A small number of patients may experience a temporary worsening of signs and symptoms of their prostate cancer and temporary increase in cancer related pain (metastatic pain), which can be managed symptomatically.</p><p>As with other GnRH agonists, isolated cases of spinal cord compression or urethral obstruction have been observed. If spinal cord compression or renal impairment develops, standard treatment of these complications should be instituted, and in extreme cases an immediate orchiectomy (surgical castration) should be considered. Careful monitoring is indicated during the first weeks of treatment, particularly in patients suffering from vertebral metastasis, at the risk of spinal cord compression, and in patients with urinary tract obstruction. For the same reason, particular care should be taken when beginning treatment in patients with premonitory signs of spinal cord compression.</p><p>After surgical castration, triptorelin does not induce any further decrease in serum testosterone levels.</p><p>Long-term androgen deprivation either by bilateral orchiectomy or administration of GnRH analogues is associated with increased risk of bone loss and may lead to osteoporosis and increased risk of bone fracture.</p><p>Androgen deprivation therapy may prolong the QT interval. In patients with a history of or risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval (see section 4.5) physicians should assess the benefit risk ratio including the potential for Torsade de pointes prior to initiating DIPHERELINE.</p><p>In addition, from epidemiological data, it has been observed that patients may experience metabolic changes (e.g. glucose intolerance), or an increased risk of cardiovascular disease during androgen deprivation therapy. However, prospective data did not confirm the link between treatment with GnRH analogues and an increase in cardiovascular mortality. Patients at high risk for metabolic or cardiovascular diseases should be carefully assessed before commencing treatment and adequately monitored during androgen deprivation therapy.</p><p>Treatment with GnRH analogues may increase risk of anemia because of androgen deprivation. This risk should be evaluated in patients treated and undertaken in a proper way.&nbsp;</p><p>Administration of triptorelin in therapeutic doses results in suppression of the pituitary gonadal system. Normal function is usually restored after treatment is discontinued. Diagnostic tests of pituitary gonadal function conducted during treatment and after discontinuation of therapy with GnRH analogues may therefore be misleading.</p><p>A transitory increase in acid phosphatases may be observed at the beginning of the treatment.</p><p>It may be advantageous to check blood testosterone levels periodically with an accurate method as these should not exceed 1 ng/ml.</p><p>In women</p><p>It should be confirmed that patient is not pregnant before prescription of DIPHERELINE P.R. 11.25 mg. The use of GnRH agonists is likely to cause reduction in bone mineral density averaging 1% per month during a six month treatment period. Every 10% reduction in bone mineral density is linked with about a two to three times increased fracture risk.</p><p>In the majority of women, currently available data suggest that recovery of bone loss occurs after cessation of therapy.</p><p>No specific data is available for patients with established osteoporosis or with risk factors for osteoporosis (e.g. chronic alcohol abuses, smokers, long-term therapy with drugs that reduce bone mineral density, e.g. anticonvulsants or corticoids, family history of osteoporosis, malnutrition, e.g. anorexia nervosa). Since reduction in bone mineral density is likely to be more detrimental in these patients, treatment with triptorelin should be considered on an individual basis and only be initiated if the benefits of treatment outweigh the risk following a very careful appraisal. Consideration should be given to additional measures in order to counteract loss of bone mineral density.</p><p>The administration, of DIPHERELINE P.R. 11.25 mg results in constant hypogonadotrophic amenorrhoea.</p><p>If genital haemorrhage occurs after the first month, plasma oestradiol levels should be measured and if levels are below 50 pg/ml, possible organic lesions should be investigated.</p><p>Since menses should stop during triptorelin treatment, the patient should be instructed to notify her physician if regular menstruation persists.</p><p>A non-hormonal method of contraception should be used throughout treatment including for 1 month after the last injection (see section 4.6).</p><p>After withdrawal of treatment, ovarian function resumes and ovulation occurs approximately 5 months after the last injection.</p><p>Central precocious puberty</p><p>Treatment of children with progressive brain tumours should follow a careful individual appraisal of the risks and benefits.</p><p>In girls initial ovarian stimulation at treatment initiation, followed by the treatment-induced oestrogen withdrawal, may lead, in the first month, to vaginal bleeding of mild or moderate intensity.</p><p>After discontinuation of treatment the development of puberty characteristics will occur.</p><p>Information with regards to future fertility is still limited. In most girls, regular menses will start on average one year after ending the therapy.</p><p>DIPHERELINE PR 11.25 mg is not indicated in transient precocious puberty as well as the normal variants of pubertal development (premature thelarche, pubarche and menarche) and isolated menstruation associated, or not, with breast development with inconsistent response to the LHRH test and presence of functioning cysts of the ovary.</p><p>Pseudo-precocious puberty (gonadal or adrenal tumour or hyperplasia) and gonadotropin-independent precocious puberty (testicular toxicosis, familial Leydig cell hyperplasia) should be precluded.</p><p>Bone mineral density (BMD) may decrease during GnRH therapy for central precocious puberty. However, after cessation of treatment subsequent bone mass accrual is preserved, and peak bone mass in late adolescence does not seem to be affected by treatment.</p><p>Slipped capital femoral epiphysis can be seen after withdrawal of GnRH treatment. The suggested theory is that the low concentrations of oestrogen during treatment with GnRH agonists weaken the epiphysial plate. The increase in growth velocity after stopping the treatment subsequently results in a reduction of the shearing force needed for displacement of the epiphysis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When triptorelin is used in combination with drugs that modify the secretion of pituitary gonadotropins, special precautions must be taken and it is recommended to close monitored with hormone assays.</p><p>Since androgen deprivation treatment may prolong the QT interval, the concomitant use of DIPHERELINE with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide ) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>Pregnancy should be excluded before DIPHERELINE is prescribed.</p><p>Triptorelin should not be used during pregnancy since concurrent use of GnRH agonists is associated with a theoretical risk of abortion or foetal abnormality. Prior to treatment, potentially fertile women should be examined carefully to exclude pregnancy. Non-hormonal methods of contraception should be employed during therapy until menses resume.</p><p><strong><u>Breast-feeding</u> </strong></p><p>Triptorelin should not be used during breast feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p style="text-indent:50px">However, the ability to drive and use machines may be impaired by dizziness, somnolence and visual disturbances which are possible undesirable effects of treatment, or resulting from the underlying disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General tolerance in men (see section 4.4)</p><p>Since patients suffering from locally advanced or metastatic, hormone-dependent prostate cancer are generally old and have other diseases frequently encountered in this aged population, more than 90 % of the patients included in clinical trials reported adverse events, and often the causality is difficult to assess.</p><p>As seen with other GnRH agonist therapies or after surgical castration, the most commonly observed adverse events related to triptorelin treatment were due to its expected pharmacological effects. These effects included hot flushes and decreased libido.&nbsp;</p><p>With the exception of immuno-allergic (rare) and injection site (&lt; 5 %) reactions, all adverse events are known to be related to testosterone changes.</p><p>The following adverse reactions, considered as at least possibly related to triptorelin treatment, were reported. Most of these events are known to be related to biochemical or surgical castration.</p><p>&nbsp;</p><p>The frequency of the adverse reactions is classified as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000). No frequency can be determined for the adverse reactions reported after marketing. Consequently, they are reported with &ldquo;frequency not known&rdquo;.</p><table border="0" cellspacing="0" cellpadding="0" style="width:642px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td><p><strong><em>Very Common </em></strong></p></td><td><p><strong><em>Common </em></strong></p></td><td><p><strong><em>Uncommon </em></strong></p></td><td><p><strong><em>Rare </em></strong></p></td><td style="vertical-align:top"><p><strong><em>Frequency not known </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nasopharyng</p><p>itis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Thrombocytosi</p><p>s</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>Anaphylactic shock</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and </strong></p><p><strong>nutrition disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p><p>Diabetes mellitus</p><p>Gout</p><p>Hyperlipidaemi a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:642px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td><p><strong><em>Very Common </em></strong></p></td><td><p><strong><em>Common </em></strong></p></td><td><p><strong><em>Uncommon </em></strong></p></td><td><p><strong><em>Rare </em></strong></p></td><td style="vertical-align:top"><p><strong><em>Frequency not known </em></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders </strong></p></td><td style="vertical-align:top"><p>Libido decreased</p></td><td style="vertical-align:top"><p>Depression*</p><p>Loss of libido</p><p>Mood changes*<em> </em>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p><p>Irritability</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Confusional state</p><p>Decreased</p><p>activity</p><p>Euphoric mood</p></td><td style="vertical-align:top"><p>Anxiety&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;Paraesthesia in lower limbs</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Headache</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Memory impairment</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual impairment</p></td><td style="vertical-align:top"><p>Abnormal sensation in eye</p><p>Visual disturbance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>QT</p><p>prolongation (see sections</p><p>4.4 and 4.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td><td style="vertical-align:top"><p>Hot flush</p></td><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p><p>Epistaxis</p></td><td style="vertical-align:top"><p>Orthopnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dry mouth</p><p>Nausea</p></td><td style="vertical-align:top"><p>Abdominal pain</p><p>Constipation</p><p>Diarrhoea</p><p>Vomiting</p></td><td style="vertical-align:top"><p>Abdominal distension</p><p>Dysgeusia</p><p>Flatulence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td><td style="vertical-align:top"><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acne</p><p>Alopecia</p><p>Erythema</p><p>Pruritus</p><p>Rash</p><p>Urticaria</p></td><td style="vertical-align:top"><p>Blister</p><p>Purpura</p></td><td style="vertical-align:top"><p>Angioneurotic oedema</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Musculoskeleta l pain</p><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>Bone pain</p><p>Muscle cramp</p><p>Muscular weakness</p></td><td style="vertical-align:top"><p>Joint stiffness</p><p>Joint swelling</p><p>Musculoskele</p><p>tal stiffness</p><p>Osteoarthritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td><p><strong><em>Very Common </em></strong></p></td><td><p><strong><em>Common </em></strong></p></td><td><p><strong><em>Uncommon </em></strong></p></td><td><p><strong><em>Rare </em></strong></p></td><td style="vertical-align:top"><p><strong><em>Frequency not known </em></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nocturia</p><p>Urinary retention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary incontinence</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders </strong></p></td><td style="vertical-align:top"><p>Erectile dysfunction (including ejaculation failure, ejaculation disorder)<strong><em> </em></strong></p></td><td style="vertical-align:top"><p>Pelvic pain</p></td><td style="vertical-align:top"><p>Gynaecomastia</p><p>Breast pain</p><p>Testicular&nbsp; atrophy</p><p>Testicular pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td><td style="vertical-align:top"><p>Asthenia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injection site reaction (including erythema, inflammation and pain)</p><p>Oedema&nbsp;</p></td><td style="vertical-align:top"><p>Lethargy&nbsp;</p><p>Oedema</p><p>peripheral Pain</p><p>Rigors</p><p>Somnolence</p></td><td style="vertical-align:top"><p>Chest pain</p><p>Dystasia</p><p>Influenza like illness</p><p>Pyrexia</p></td><td style="vertical-align:top"><p>Malaise</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight increased</p></td><td style="vertical-align:top"><p>Alanine aminotransfera se increased</p><p>Aspartate aminotransfera se increased</p><p>Blood creatinine increased</p><p>Blood pressure increased</p><p>Blood urea increased</p><p>Gammaglutamyl transferase increased</p><p>Weight decreased</p></td><td style="vertical-align:top"><p>Blood</p><p>alkaline phosphatase increased</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* This frequency is based on class-effect frequencies common for all GnRH agonists</p><p>Triptorelin causes a transient increase in circulating testosterone levels within the first week after the initial injection of the sustained release formulation. With this initial increase in circulating testosterone levels, a small percentage of patients (&le; 5%) may experience a temporary worsening of signs and symptoms of their prostate cancer (tumour flare), usually manifested by an increase in urinary symptoms (&lt; 2%) and metastatic pain (5%), which can be managed symptomatically. These symptoms are transient and usually disappear in one to two weeks.&nbsp;</p><p>Isolated cases of exacerbation of disease symptoms, either urethral obstruction or spinal cord compression by metastasis have occurred. Therefore, patients with metastatic vertebral lesions and/or with upper or lower urinary tract obstruction should be closely observed during the first few weeks of therapy (see section 4.4).</p><p>The use of GnRH agonists, to treat prostate cancer may be associated with increased bone loss and may lead to osteoporosis and increases the risk of bone fracture.&nbsp;</p><p>An increase in lymphocytes has been reported in patients treated with GnRH analogues. This secondary lymphocytosis is apparently related to castration induced by GnRH and suggests that gonadal hormones are involved in thymic involution.</p><p>Patients receiving long-term treatment by GnRH analogue in combination with radiation may have more side effects especially gastrointestinal, related to radiotherapy.</p><p>General tolerance in women (see section 4.4)</p><p>As a consequence of decreased oestrogen levels, the most commonly reported adverse events (expected in 10% of women or more) were headache, libido decreased, sleep disorder, mood altered, dyspareunia, dysmenorrhoea, genital haemorrhage, ovarian hyperstimulation syndrome, ovarian hypertrophy, pelvic pain, abdominal pain, vulvovaginal dryness, hyperhidrosis, hot flushes and asthenia.</p><p>The following adverse reactions, considered as at least possibly related to triptorelin treatment, were reported. Most of these are known to be related to biochemical or surgical castration.</p><p>The frequency of the adverse reactions is classified as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10). No frequency can be determined for the adverse reactions reported after marketing. Consequently, they are reported with frequency &ldquo;not known&rdquo;.</p><table border="0" cellspacing="0" cellpadding="0" style="width:681px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td><p><strong>Very Common </strong></p></td><td><p><strong>Common </strong></p></td><td><p><strong>Uncommon </strong></p></td><td><p><strong>Frequency not known </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Anaphylactic shock</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and </strong></p><p><strong>nutrition disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased appetite</p><p>Fluid retention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders </strong></p></td><td style="vertical-align:top"><p>Sleep disorder (including insomnia)</p><p>Mood altered</p><p>Libido decreased</p></td><td style="vertical-align:top"><p>Depression*</p><p>Nervousness</p></td><td style="vertical-align:top"><p>Affect lability</p><p>Anxiety</p><p>Depression**</p><p>Disorientation</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Confusional state</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td><td style="vertical-align:top"><p>Headache</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Dysgeusia</p><p>Hypoasthesia Syncope&nbsp;</p><p>Memory impairment Disturbance in attention&nbsp;</p><p>Paraesthesia&nbsp;</p><p>Tremor</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dry eye</p><p>Visual impairment</p></td><td style="vertical-align:top"><p>Visual disturbance</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td><td style="vertical-align:top"><p>Hot flush</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:681px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td><p><strong>Very Common </strong></p></td><td><p><strong>Common </strong></p></td><td><p><strong>Uncommon </strong></p></td><td><p><strong>Frequency not known </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p><p>Epistaxis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea</p><p>Abdominal pain&nbsp;</p><p>Abdominal discomfort</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal</p><p>distension&nbsp;&nbsp; Diarrhoea</p><p>Dry mouth&nbsp;</p><p>Flatulence&nbsp;</p><p>Mouth ulceration</p><p>Vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td><td style="vertical-align:top"><p>Acne</p><p>Hyperhidrosis</p><p>Seborrhoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alopecia&nbsp;</p><p>Dry skin</p><p>Hirsutism&nbsp;</p><p>Onychoclasis</p><p>Pruritus&nbsp;</p><p>Rash</p></td><td style="vertical-align:top"><p>Angioneurotic oedema</p><p>&nbsp;</p><p>Urticaria</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>Muscle spasms&nbsp;</p><p>Pain extremities</p></td><td style="vertical-align:top"><p>Back pain</p><p>Myalgia</p></td><td style="vertical-align:top"><p>Muscular weakness&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders </strong></p></td><td style="vertical-align:top"><p>Breast disorder</p><p>Dyspareunia&nbsp;</p><p>Genital bleeding (including vaginal bleeding, privation haemorrhage),</p><p>Ovarian hyperstimulation syndrome</p><p>Ovarian hypertrophy Pelvic pain</p><p>Vulvovaginal dryness&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Breast pain</p></td><td style="vertical-align:top"><p>Coital bleeding</p><p>Cystocele&nbsp;</p><p>Menstrual disorder (including dysmenorrhoea, metrorrhagia and menorrhagia)</p><p>Ovarian cyst&nbsp;</p><p>Vaginal discharge</p></td><td style="vertical-align:top"><p>Amenorrhoea</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Injection site reaction</p><p>(including pain, swelling, erythema and inflammation)&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia</p><p>Malaise</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:681px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td><p><strong>Very Common </strong></p></td><td><p><strong>Common </strong></p></td><td><p><strong>Uncommon </strong></p></td><td><p><strong>Frequency not known </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema</p><p>peripheral</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight increased</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p><p>Blood pressure increased</p></td></tr></tbody></table><p><em>*Long term use. </em>This frequency is based on class-effect frequencies common for all GnRH agonists<em> </em></p><p><em>** Short term use. </em>This frequency is based on class-effect frequencies common for all GnRH agonits<em> </em></p><p>&nbsp;</p><p>At the beginning of treatment, the symptoms of endometriosis including pelvic pain, dysmenorrhoea may be exacerbated very commonly (&ge; 10%) during the initial transient increase in plasma oestradiol levels. These symptoms are transient and usually disappear in one or two weeks.</p><p>Genital haemorrhage including menorrhagia, metrorrhagia may occur in the month following the first injection.</p><p>Long-term use of GnRH analogues may lead to bone loss which is a risk factor of osteoporosis.</p><p>General tolerance in children (see section 4.4)&nbsp;</p><p>As seen with other GnRH agonist therapies, the most commonly observed adverse events related to triptorelin treatment in clinical trials were due to its expected pharmacological effects. These effects included vaginal bleeding that could be of low intensity (spotting).</p><p>The following adverse reactions, considered as at least possibly related to triptorelin treatment, were reported.&nbsp;</p><p>The frequency of the adverse reactions is classified as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100). No frequency can be estimated for the adverse reactions reported after marketing. Consequently they are reported with &ldquo;frequency not known&rdquo;.</p><table border="0" cellspacing="0" cellpadding="0" style="width:631px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td><p><strong><em>Very Common </em></strong></p></td><td><p><strong><em>Common </em></strong></p></td><td><p><strong><em>Uncommon </em></strong></p></td><td style="vertical-align:top"><p><strong><em>Frequency not known </em></strong></p></td></tr><tr><td><p><strong>Immune system disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>Hypersensitivity <strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic shock (seen in adult men and women)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and </strong></p><p><strong>nutrition disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Obesity</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Psychiatric disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Mood altered</p></td><td style="vertical-align:top"><p>Affect lability</p><p>Depression</p><p>Nervousness&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>Headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Vision impairment</p></td><td style="vertical-align:top"><p>Visual disturbance</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hot flush</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>Hypertension</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>&nbsp;</strong></p></td><td><p>Epistaxis</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Gastrointestinal disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Constipation</p><p>Nausea</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>Acne</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Rash</p><p>Urticaria</p></td><td style="vertical-align:top"><p>Angioneurotic</p><p>oedema</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Neck pain</p></td><td><p>Myalgia</p></td></tr><tr><td><p><strong>Reproductive system and breast disorders </strong></p></td><td style="vertical-align:top"><p>Vaginal bleeding (including vaginal haemorrhage), Withdrawal bleed, Uterine haemorrhage,</p><p>Vaginal discharge, Vaginal bleeding including spotting)</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Breast pain</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>General disorders and administration site conditions </strong></p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injection site reaction (including injection site pain, injection site</p><p>erythema and</p><p>injection site inflammation)</p></td><td><p>Malaise</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Investigations </strong></p></td><td><p>&nbsp;</p></td><td><p>Weight increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood prolactin increased Blood pressure</p><p>increased</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Vaginal bleeding may occur in the month following the first injection.</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: Agence nationale de s&eacute;curit&eacute; du m&eacute;dicament et des produits de sant&eacute; (ANSM) and the network of the Centres R&eacute;gionaux de Pharmacovigilance &ndash; Internet site: www.ansm.sante.fr.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If overdose occurs, symptomatic management is indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: gonadotrophin-releasing hormone analogue </strong></p><p><strong>ATC code: L02AE04 </strong></p><p>Triptorelin is a synthetic decapeptide analogue of natural GnRH (gonadotrophin-releasing hormone).</p><p>Studies conducted in both humans and animals have shown that after initial stimulation, the prolonged administration of triptorelin inhibits gonadotrope secretion with consequent suppression of testicular and ovarian function.</p><p>The administration of DIPHERELINE P.R. 11.25 mg may initially increase blood LH and FSH levels and may consequently increase initial testosterone level (flare-up) in men and oestradiol level in women. Continuing the treatment decreases LH and FSH levels leading to decreased testosterone and oestradiol levels similar to those observed after castration within about 20 days after the injection and for as long as the active substance is released.</p><p>Prostate Cancer</p><p>An opened, not controlled and multicentric phase 3 clinical trial involving 126 patients with advanced prostate cancer has been conducted during 6 months in order to assess the efficacy of subcutaneous administration of DIPHERELINE P.R. 11.25 (one administration every 3 months). After four weeks 97.6% of subjects were castrated (testosterone levels &lt;50 ng/dL) (95% CI: [93.2; 99.5]) and castration was maintained at Month 6 in 96.6% of subjects (95%CI: [91.6; 99.1]) (coprimary endpoints). The probability for a subject to be castrated within the first month of treatment and to remain castrated at each measurement up to 6 months was 96% (95%CI [0.92, 0.99]) (see Figure 1).</p><p><u>Figure 1 Kaplan-Meier Plot for Probability of Testosterone &lt; 50 ng/dL from Day 29 through Day 183</u> <u>after subcutaneous administration</u></p><p><img src="data:image/png;base64,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" alt="" width="609" height="802" vspace="0" hspace="0" border="0" style="width:609px;height:802px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>During the treatment by triptorelin, median PSA levels were reduced by 64.2% at Month 1 and by 96% at Month 6 (secondary endpoint). Median PSA values remained within normal range (0-4 ng/mL) from Month 2 until the end of the study.</p><p>In patients with locally advanced prostate cancer several randomized long-term clinical trials provide evidence for the benefit of androgen deprivation therapy (ADT) in combination with radiotherapy (RT) compared to RT alone (RTOG 85-31, RTOG 86-10, EORTC 22863, D&rsquo;Amico et al., JAMA, 2008).</p><p>A randomized phase III study (EORTC 22961) of 970 patients with prostate cancer locally advanced (mainly T2c-T4 with some T1C to T2B patients with pathological regional nodale disease) has investigated whether radiation therapy associated with short term androgen deprivation therapy (6 months, n = 483) was non-inferior to radiotherapy associated with long term androgen deprivation therapy (3 years, n = 487). The GnRH agonist was triptorelin (62.2%) or other GnRH agonists (37.8%) and the trial was not further stratified by the type of agonist.&nbsp;</p><p>Overall, total mortality at 5 years was 19.0% and 15.2% respectively in the &quot;short term hormonal treatment&quot; and &quot;long term hormonal treatment&quot; groups, with a relative risk of 1.42 (CI-sided 95, 71% = 1.79; 95.71% CI = [1.09; 1.85], p = 0.65 for noninferiority and p = 0.0082 for post-hoc test of difference between groups of treatment). The 5-year mortality specifically related to the prostate was 4.78% and&nbsp; 3.2% respectively in the &quot; short term hormonal treatment &quot;and&quot; long term hormonal treatment&quot; groups, with a relative risk of 1.71 (CI 95% [1.14 to 2.57], p = 0.002). Overall quality of life using QLQ-C30 did not differ significantly between the two groups (P= 0.37).</p><p>The post hoc analysis in the subgroup triptorelin also show the advantage of the long term treatment versus the short term treatment on overall mortality (relative risk 1.28; 95.71% CI = [0.89 ; 1.84], p = 0.38 and p = 0.08 respectively for noninferiority post-hoc tests and for difference between treatment groups).</p><p>&nbsp;Evidence for the indication of high-risk localised prostate cancer is based on published studies of radiotherapy combined with GnRH analogues. Clinical data from five published studies were analyzed (EORTC 22863, RTOG 85-31, RTOG 92-02, RTOG 86-10, and D&rsquo;Amico et al., JAMA, 2008), which all demonstrate a benefit for the combination of GnRH analogue with radiotherapy. Clear differentiation of the respective study populations for the indications locally advanced prostate cancer and high-risk localised prostate cancer was not possible in the published studies.</p><p>For patients with metastatic prostate cancer castration-resistant, clinical trials have shown the benefice of adding androgen biosynthesis inhibitors as abiraterone acetate or inhibitors of signaling pathway of androgen receptors as enzalutamide to the treatment by a GnRH analog as triptorelin.</p><p>Endometriosis</p><p>Continued administration of DIPHERELINE SR 11.25 mg induces suppression of oestrogen secretion and thus enables resting of ectopic endometrial tissue in women.&nbsp;</p><p>Pediatric population<em> </em>&ndash;<em> </em>precocious puberty<em> </em></p><p>The inhibition of hypophyseal gonadotrophic hyperactivity in both sexes manifests as suppression of oestradiol or testosterone secretion, as a lowering of the LH peak and as improved Height Age /Bone Age ratio.</p><p>Initial gonadic stimulation may cause slight genital haemorrhages requiring medroxyprogesterone or cyproterone acetate treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following intramuscular injection of DIPHERELINE P.R. 11.25 mg in patients (men and women), a peak plasma concentration of triptorelin is observed about 3 hours after injection. After a declining concentration phase, which continues during the first month, circulating triptorelin levels remain constant until the end of the third month following the injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The molecule did not demonstrate any specific toxicity in animal toxicological studies. The effects observed are related to the pharmacological properties of the substance on the endocrine system.</p><p>The resorption of the product is complete in 120 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>D,L lactide coglycolide polymer; mannitol; sodium carmellose; polysorbate 80.</p><p><u>Solvent</u>: mannitol, water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>To be injected immediately after reconstitution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-indent:50px">Powder in 4ml vial ml (glass type I) with a stopper (elastomer) and a cap (aluminium) + 2 ml of solvent in ampoule (glass); Box containing 1 vial and 1 ampoule with 1 syringe and 2 needles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The powder should be suspended in the specific solvent immediately before injection by shaking the vial gently until a milky homogeneous liquid is obtained (The instructions for reconstitution hereafter and in the leaflet must be strictly followed.&nbsp; ).</p><p>o <em>For single </em>use<em> only. Any unused</em> suspension should be discarded.An overfill is included to allow for this loss.</p><p>The powder is to be suspended in 2 ml of mannitol solution:</p><p>Using the reconstitution needle (20 G, without safety device), one of the injection needles, all of the solvent is drawn up into the injection syringe supplied and transferred to the vial containing the powder. The vial should be gently shaken to completely disperse the powder to obtain a homogenous, milky suspension. The suspension obtained is then drawn back into the injection syringe. The injection needle&nbsp; (20G, with safety device) should be changed and the suspension should be injected immediately.</p><p>&nbsp;</p><p>The suspension should be discarded if it is not administered immediately after reconstitution. See also section 6.3.</p><p>Used injection needles should be disposed in a designated sharp container. Any remaining product should be discarded.</p><p>Used needles, any unused suspension or other waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                IPSEN PHARMA 
65 QUAI GEORGES GORSE 
92100 BOULOGNE-BILLANCOURT 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                {DD month YYYY} 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>